Common Misconceptions About Visceral Fat
Visceral fat is not a single substance but a depot of adipose tissue. This research-supply catalogue article reviews misconceptions and the studies that address them.
What Visceral Fat Is
Visceral fat is the adipose tissue stored within the abdominal cavity, surrounding internal organs such as the liver, pancreas, and intestines. It is distinct from subcutaneous fat, which lies beneath the skin. In the research literature, visceral fat is often quantified as visceral fat area (VFA) or as ectopic fat in specific organs, including hepatic fat and pancreatic fat. Unlike subcutaneous fat, visceral fat drains into the portal circulation and is associated with inflammatory and metabolic markers. The evidence block for this page does not provide a sequence, formula, or molecular weight for visceral fat because it is a tissue depot, not a single molecule.
The work reviewed here centres on adipose tissue dysfunction and its relationship to insulin resistance, type 2 diabetes, and cardiometabolic risk, with pathways involving adipokines such as resistin, leptin, irisin, and sclerostin, as well as gut-derived compounds and incretin receptor agonists.
Research Studies
Mazdutide and Fatty Pancreas in Overweight or Obesity
A randomized, double-blind, placebo-controlled, parallel-group, single-centre clinical trial is designed to evaluate the efficacy and safety of mazdutide in improving fatty pancreas in patients with overweight or obesity. The study plans to enrol 194 participants, randomly assigned 1:1 to mazdutide plus standardized lifestyle intervention or placebo plus standardized lifestyle intervention, for 48 weeks. The primary efficacy endpoint is the change from baseline in pancreatic proton density fat fraction (PDFF) measured by MRI at week 48. Secondary endpoints include changes in body composition and metabolic parameters [1].
Mazdutide and Nonalcoholic Fatty Liver Disease in Type 2 Diabetes After Semaglutide
A multicentre, prospective, randomized controlled investigator-initiated trial is evaluating the efficacy and safety of switching to mazdutide therapy in Chinese patients with type 2 diabetes mellitus and moderate-to-severe nonalcoholic fatty liver disease who have achieved glycemic control. The background notes that Chinese patients with type 2 diabetes are susceptible to visceral fat accumulation, which increases the risk of cardiometabolic diseases and mortality, and that metabolic associated fatty liver disease is highly prevalent in this population [2].
Sclerostin, Irisin, and Leptin in Chinese Men With Obesity
A cross-sectional study explored the interactions among sclerostin, irisin, and leptin, and their associations with body composition and bone metabolism in Chinese men with obesity. The study included 26 men with normal weight and 78 men with obesity. Body composition was measured using dual-emission X-ray absorptiometry, and subcutaneous fat, visceral fat, and fat content in the liver and pancreas were determined by magnetic resonance. Serum sclerostin, irisin, and leptin were detected using ELISA. Compared with men with normal weight, serum sclerostin, irisin, and leptin levels as well as whole-body and spinal bone mineral density differed [3].
BMI Versus Body Fat Percentage and IVF Outcomes
A prospective observational cohort study is evaluating whether body composition measured using bioelectrical impedance analysis (BIA), including body fat percentage and visceral fat, serves as a better predictor than body mass index (BMI) of outcomes of in vitro fertilization (IVF) cycles. Participants undergoing IVF will have body composition assessed using a BIA scale prior to treatment. Outcomes of interest include ovarian stimulation requirements, number of mature oocytes retrieved, number of oocytes fertilized, and other IVF treatment outcomes [4].
Urolithin A and Muscle Preservation During Restricted Eating in Obesity
A study is testing whether daily Urolithin A (500 mg) for 6 months helps adults with obesity lose weight while preserving functional muscle mass and improving markers of mitochondrial health, inflammation, and metabolism. All participants receive the same structured lifestyle program (nutrition and sleep guidance); half receive Urolithin A and half a matching placebo. The background notes that weight loss can improve health but may also reduce skeletal muscle, especially in people with obesity, and that aging and obesity are linked to mitochondrial dysfunction, impaired autophagy/mitophagy, oxidative stress, and low-grade inflammation. Urolithin A is a gut-derived, diet-related compound [5].
Resistin and Visceral Fat Reduction After Sleeve Gastrectomy
A study aims to investigate whether resistin, a protein in the blood, can help predict how much visceral fat a patient will lose following sleeve gastrectomy. Sleeve gastrectomy is a common and effective procedure that reduces the stomach's size to help patients lose weight and improve metabolic health. Beyond weight loss, reducing visceral fat—the fat stored around internal organs—is vital because it is closely linked to inflammation and conditions like type 2 diabetes. Resistin is a marker known to contribute to insulin resistance and is typically higher in individuals with significant abdominal fat. The study measures resistin levels before surgery [6].
Barley Green and Visceral Fat Area in High Body Fat Percentage
A study investigated changes in visceral fat area and associated indicators in individuals with high body fat percentage under intervention with barley green, to elucidate clinical efficacy on human visceral fat and preliminarily explore the mechanism through gut microbiota analysis. Participants with high body fat percentage were recruited from the Clinical Nutrition Department of Peking University People's Hospital and randomly assigned to an intervention group or a control group. The intervention group received a regimen combining barley green supplementation with a calorie-restricted diet [7].
Ethnic Differences in Adipose Tissue Dysfunction and Type 2 Diabetes
A pilot study investigates the relationship between type 2 diabetes and adipose tissue dysfunction across different ethnic groups. Adipose tissue dysfunction is characterised by abnormal fat distribution, including increased visceral, hepatic, and pancreatic fat, elevated inflammatory biomarkers, and impaired metabolic function. Type 2 diabetes is a chronic metabolic disease characterised by insulin resistance and disrupted glucose regulation. In the UK, its prevalence is significantly higher among South Asian and Black African/Caribbean populations than among White Europeans. Differences in adipose tissue distribution, particularly increased visceral fat accumulation, are thought to contribute [8].
Comparison of Visceral Fat Measures Across Studies
| Study | Population | Measure of Visceral Fat | Intervention/Exposure |
|---|---|---|---|
| NCT07803705 [1] | Overweight or obesity | Pancreatic PDFF by MRI | Mazdutide vs placebo |
| NCT07713992 [2] | Chinese T2DM with NAFLD | Not specified in excerpt | Mazdutide switch |
| PMC13443498 [3] | Chinese men with obesity | Visceral fat by MRI | Cross-sectional |
| NCT07765368 [4] | IVF patients | Visceral fat by BIA | Observational |
| NCT07377136 [5] | BMI >30 | Not specified in excerpt | Urolithin A 500 mg |
| NCT07564986 [6] | Morbid obesity | Visceral fat reduction | Sleeve gastrectomy |
| NCT06886048 [7] | High body fat percentage | Visceral fat area | Barley green |
| NCT07666321 [8] | Multiple ethnic groups | Visceral, hepatic, pancreatic fat | Observational |
Reference-Only Findings on Visceral Fat
Additional studies report on visceral fat in specific clinical contexts. One study examined circulating adipokines, tissue receptor expression, and body composition in epithelial ovarian carcinoma, integrating these with nutritional status and disease stage [9]. Another reported that a bitter hop nutraceutical stimulated fat mass loss while preserving muscle mass in a cohort of individuals with overweight or obesity receiving diet and exercise advice [10]. A third described differing presentations of excess visceral abdominal fat in people living with HIV, highlighting distinct therapeutic pathways with tesamorelin and glucagon-like peptide-1 receptor agonists [11]. A fourth reported hematopoietic stem cell transplantation-associated partial lipodystrophy, a metabolic complication in childhood cancer survivors treated with total body irradiation [12]. These findings are reported here as facts from the respective studies; they are not the focus of this page.
If you are reading this for personal health reasons
The materials and compounds discussed here are sold for laboratory research use only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Efficacy of Mazdutide on Fatty Pancreas
- [2] Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide
- [3] Serum Bone-, Muscle- and Fat- Derived Factors Sclerostin, Irisin and Leptin Show Different Correlations With Body Composition and Bone Mineral Density in Chinese Men With Obesity: A Cross-Sectional Study.
- [4] BMI Versus Body Fat Percentage - Which is the Better Predictor of Fertility Outcomes in IVF Cycles?
- [5] Influence of the Urolithin A on the Population With BMI Higher Than 30 During Restricted Eating.
- [6] Relationship Between Serum Resistin Levels and Reduction in Visceral Fat in Patients Undergoing Sleeve Gastrectomy Due to Morbid Obesity
- [7] Effects of Barley Green on Visceral Fat Area in the Human Body and Investigation Into the Associated Mechanism of Intestinal Microbiota
- [8] Ethnic Differences in Adipose Tissue Dysfunction in the Development of Insulin Resistance and Type 2 Diabetes
- [9] Circulating Adipokines, Tissue Receptor Expression, and Body Composition: Clinical Relevance and Disease Stage in Epithelial Ovarian Carcinoma.
- [10] Bitter hop nutraceutical stimulates fat mass loss while preserving muscle mass in a cohort of individuals with overweight or obesity receiving diet and exercise advice.
- [11] Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists.
- [12] Hematopoietic stem cell transplantation-associated partial lipodystrophy.